ClinicalTrials.Veeva

Menu
C

Centre de Recherche Saint-Louis | Clinique Medicale Saint-Louis

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Metformin
Sugar
Rocatinlimab
PF-06882961
PF-05221304
Ritlecitinib
Tirzepatide
Abrocitinib
PF-06651600
PF-06700841

Parent organization

This site is a part of Centre de Recherche Saint-Louis

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 40 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjec...

Enrolling
Alopecia Areata (AA)
Drug: ALD-102
Drug: Placebo

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Enrolling
Diabetes Mellitus, Type 2
Drug: Cagrilintide
Drug: Semaglutide

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Placebo semaglutide
Drug: Semaglutide

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Active, not recruiting
Prurigo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream
Locations recently updated

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with at...

Not yet enrolling
Atopic Hand and Foot Dermatitis
Drug: Lebrikizumab
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315
Locations recently updated

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whe...

Enrolling
Pyoderma Gangrenosum
Drug: Prednisolone
Drug: Prednisone

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

Trial sponsors

Pfizer logo
Novo Nordisk logo
Amgen logo
A
Bayer logo
Boehringer Ingelheim logo
Concert Pharmaceuticals logo
Incyte logo
Lilly logo
Moderna logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems